COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.

Overview

Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ transplant recipients (SOTR) are not well described in the literature. The objective of this analysis was to characterize 30-day hospitalization and other key secondary endpoints experienced by outpatient SOTR with mild-moderate COVID-19 treated with nirmatrelvir/ritonavir (NR), sotrovimab, or no SARS-CoV-2 specific treatment. This IRB-approved, retrospective study included 154 SOTR with a documented positive SARS-CoV-2 infection between 12/16/2021 and 1/19/2022 (a predominant Omicron BA.1 period in New York City). Patients who received NR (N=28) or sotrovimab (N=51) experienced a lower rate of 30-day hospitalization or death as compared to those who received no specific treatment (N=75) (P=0.009). A total of 3 deaths occurred, all among patients who initially received no specific treatment prior to hospitalization. These results suggest a role for SARS-CoV-2 specific agents for the treatment of SOTR with COVID-19, and that there does not appear to be any difference in effectiveness when comparing NR versus sotrovimab.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Journal